CAS: 87056-78-8; 3-(Diethylsulfamoylamino)-6-Hydroxy-1-Propyl-3,4,4A,5,10,10A-Hexahydro-2H-Benzo[g]Quinoline

该化合物是一种合成化合物,主要用作多巴胺的催化剂,具体针对D2多巴胺受体,其特征是能够抑制蛋白分泌,使其在治疗超蛋白性贫血和某些类型的垂体肿瘤等条件下有用. Quinagolide通常以口头方式施用,以其相对选择性的行动而著称,这种行动最大限度地减少了与更广泛的多巴胺受体活化有关的副作用. 该化合物具有中度分子重量和展示的亲脂性,允许在体内有效吸收和分布. 其药用植物动力学学涉及肝细胞代谢,主要通过尿液排出. 与许多药剂一样,在治疗过程中,监测潜在的副作用,包括腹泻,眩晕和疲劳等,是至关重要的. 总的来说, Quinagolide是内分泌学中的一个重要治疗选择, 特别是用于控制与蛋白性紊乱有关的疾病.

结构式图片

MSDS等安全信息

    上下游产品

    CAS号87056-75-5 (+/-)-N,N-dieth... | CAS号87098-97-3 (+/-)-(3α,4aα,1... | CAS号87056-65-3 (+/-)-(3α,4aα,1... | CAS号87056-66-4 (+/-)-(3α,4aα,1... | CAS号87056-77-7 (+/-)-(((3α,4aα... | CAS号87056-74-4 (+/-)-(3α,4aα,1...

    合成工艺路线路线简述

    • 合成目标产物 Quinagolide 主要起始原料 (+/-)-(3α,4Aα,10Aβ)-1,2,3,4,4A,5,10,10A-Octahydro-6-Methoxy-3-(Methoxycarbonyl)Benzoquinoline
    • (文献来源)合成步骤主要原料 (+/-)-(3α,4Aα,10Aβ)-1,2,3,4,4A,5,10,10A-Octahydro-6-Methoxy-3-(Methoxycarbonyl)Benzoquinoline

    海关参考信息

    专利信息


    专利号:WO-2024153752-A1
    优先权日:2023-01-20
    标 题 :Stereoselective synthesis of intermediates and synthesis of quinagolids
    发明人:RYBERG PER; PINESCHI MAURO; COMPARINI LUCREZIA
    权利人:FERRING BV
    摘要:Disclosed is a method for preparing compounds with improved stereoselectivities. The described compounds are useful intermediates and may find particular application in the synthesis of compounds containing an octahydrobenzoquinoline moiety (e.g. an octahydrobenzo[g]quinoline moiety), such as quinagolide and its derivatives. Also disclosed is a method for stereoselectively (e.g. enantioselectively) preparing an intermediate used in the existing manufacturing process for the synthesis of quinagolide this intermediate also finding utility in the synthesis of other compounds containing an octahydrobenzo[g]quinoline moiety, in particular those having a substituent at the 3- position on the octahydrobenzo[g]quinoline.

    专利号:WO-0054773-A1
    优先权日:1999-03-12
    标题:Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
    发明人:GARVEY DAVID S
    权利人:NITROMED INC; GARVEY DAVID S
    摘要:The present invention is directed to novel compositions comprising at least one dopamine agonist in combination with at least one nitric oxide donor (i.e. compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are substrates for nitric oxide synthase). The novel compositions may optionally comprise at least one therapeutic agent, such as, a vasoactive agent, an antimetic agent, and mixtures thereof. The dopamine agonist is preferably apomorphine. The present invention is also directed to methods for treating and/or preventing sexual dysfunctions and/or enhancing sexual responses in patients. In other embodiments, the present invention is directed to methods treating or preventing neurodegenerative diseases, mitochondrial diseases, spinal cord injury, central or psychostimulant addiction, senile dementia, circulatory disorders, cardiovascular disorders, hyperprolactinaemia or myopia. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

    专利号:US-2022118123-A1
    优先权日:2019-02-22
    标 题 :Combination of ar antagonists and targeted thorium conjugates
    发明人:HAMMER STEFANIE; HAGEMANN URS BEAT; HAENDLER BERNARD; LEJEUNE PASCALE; ZITZMANN-KOLBE SABINE; SCHATZ CHRISTOPH; KARLSSON JENNY
    权利人:BAYER AG; BAYER AS
    摘要:The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.

    专利号:US-2023271983-A1
    优先权日:2020-07-29
    标题 :Functionalized isonitriles and products, preparation and uses thereof
    发明人:SOTELO PÉREZ EDDY; AZUAJE GUERRERO JHONNY ALBERTO; MAJELLARO MARIA
    权利人:UNIV SANTIAGO COMPOSTELA
    摘要:The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorophore molecules. The invention also relates to conjugates between said isonitrile compounds and functional molecules, which are useful in the synthesis of pharmaceutic drugs or tools, fluorescent molecules and labels, polymeric smart materials. The invention furthermore provides a kit for the in-vitro preparation of the functionalized isontrile compounds and conjugates. The invention also contemplates the medical use of said compounds and conjugates.

    专利号:US-2014315720-A1
    优先权日:2012-10-24
    标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
    发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
    权利人:CELANESE ACETATE LLC
    摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Boutinaud M, Lollivier V, Finot L, Bruckmaier RM, Lacasse P. Mammary cell activity and turnover in dairy cows treated with the prolactin-release inhibitor quinagolide and milked once daily. J Dairy Sci. 2012 Jan;95(1):177-87. doi: 10.3168/jds.2011-4461. e1-3. doi: 10.1016/j.genhosppsych.2011.07.004. Epub 2011 Aug 26. doi: 10.3168/jds.2010-3649. e1. doi: 10.1016/j.fertnstert.2010.10.024. Epub 2010 Nov 5. doi: 10.1556/OH.2010.28896. Hungarian. doi: 10.1093/humrep/deq005. Epub 2010 Feb 6.
    7: Vinkers DJ, van der Wee NJ. A case of mania after long-term use of quinagolide. Gen Hosp Psychiatry. 2007 Sep-Oct;29(5):464. Review.

    合成参考文献


    摘要:Ochoa, C. I.; Tambar, U. K., Science of Synthesis Knowledge Updates, (2020) 2, 345.
    参考文献:10.3168/jds.2014-7914
    摘要:Ollier S, Zhao X, Lacasse P. Effects of feed restriction and prolactin-release inhibition at drying off on metabolism and mammary gland involution in cows. Journal of Dairy Science. 2014 Aug;97(8):4942–54. doi: 10.3168/jds.2014-7914.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知